Alaska Blueberry (Vaccinium alaskaense), like other wild blueberries, is sometimes promoted for cognitive health, including dementia support, based primarily on its high content of anthocyanins and other polyphenols. There is a growing body of scientific literature indicating that blueberries can have neuroprotective effects, largely due to their antioxidant and anti-inflammatory properties. Some preclinical studies and a few small human trials suggest that regular blueberry consumption may improve cognitive function and delay cognitive decline in older adults. However, most studies have been conducted with cultivated blueberries (Vaccinium corymbosum or Vaccinium angustifolium), not specifically with Alaska Blueberry. There is limited direct evidence regarding Alaska Blueberry itself, but as it is closely related botanically and chemically, it is reasonable to extrapolate some potential benefit.

Despite these promising findings, the data are preliminary. Clinical trials specifically addressing blueberry supplementation for dementia prevention or treatment are few and generally small. As such, while there is some scientific validation for blueberries broadly supporting cognitive health and potentially reducing dementia risk, high-quality evidence for a therapeutic effect – especially with Alaska Blueberry – is currently lacking. More research is needed to confirm efficacy, optimal dosage, and mechanisms of action in humans.